Traditional Chinese medicine composition for treating hyperuricemia nephropathy

Abstract

The invention discloses a traditional Chinese medicine composition for treating hyperuricemia nephropathy, and relates to the technical field of traditional Chinese medicines, and the key point of the technical scheme is that the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 15-45g of rhizoma smilacis glabrae, 10-20g of poria cocos, 10-20g of semen coicis, 5-15g of rhizoma atractylodis and 3-9g of liquorice. The traditional Chinese medicine composition disclosed by the invention has the effects of clearing heat, promoting diuresis and promoting uric acid excretion, can help to reduce the level of serum uric acid so as to relieve hyperuricemia, and can help to improve kidney functions and relieve damage to kidneys caused by too high uric acid.

Description

Technical Field

[0001] The present invention relates to the technical field of traditional Chinese medicines, and more particularly to a traditional Chinese medicine composition for treating hyperuricemia nephropathy. Background Art

[0002] Hyperuricemia nephropathy (HUA-CKD) is a chronic kidney disease caused by uric acid metabolism disorders in the body. Increased uric acid levels not only cause gout, but also cause damage to kidney function, and may eventually lead to chronic renal failure. Clinically, the treatment of hyperuricemia nephropathy usually includes drug therapy, diet control, and lifestyle adjustments. However, due to certain side effects and drug resistance problems of Western medicine treatment, more and more researchers and clinicians have begun to pay attention to the application of traditional Chinese medicine in the treatment of hyperuricemia nephropathy.

[0003] Modern pharmacological studies have shown that various ingredients in traditional Chinese medicine have unique mechanisms of action in the treatment of hyperuricemia and related kidney diseases. Some ingredients in traditional Chinese medicine can reduce the production of uric acid by inhibiting the activity of xanthine oxidase. Some traditional Chinese medicines accelerate the excretion of uric acid and reduce blood uric acid levels by increasing the excretion function of the renal tubules. Some ingredients in traditional Chinese medicine have strong antioxidant and anti-inflammatory effects, which can reduce the inflammatory response of the kidneys and protect kidney tissue. Some traditional Chinese medicines can improve renal microcirculation and prevent further deterioration of renal function by dilating blood vessels and improving blood rheological properties.

[0004] According to TCM, the pathogenesis of hyperuricemia nephropathy is related to spleen deficiency, kidney deficiency, and internal accumulation of dampness and heat. When the spleen fails to function properly, water and dampness cannot be transformed, and dampness and turbidity accumulate. Over time, they turn into heat, and the accumulated heat turns into fire, which eventually leads to the accumulation of dampness and heat, and the disturbance of turbidity, thus affecting the function of the kidneys. The kidney is the foundation of the body and is responsible for water metabolism. If the kidney is deficient, the qi transformation is powerless, and water and dampness stagnate inside, leading to uric acid metabolism disorders. Based on traditional and modern research results and TCM theories, many Chinese medicine compositions have been developed in recent years. Based on different pathological mechanisms, multi-target and multi-pathway treatment strategies are adopted. These compositions usually contain a variety of synergistic Chinese medicine ingredients, which can reduce side effects while improving the treatment effect.

[0005] The present invention finds that a Chinese medicinal composition consisting of Rhizoma Smilacis Glabrae, Poria cocos, Coix seeds, Atractylodes macrocephala and Licorice and a Chinese medicinal composition prepared by using the formula of the Chinese medicinal composition can help lower serum uric acid levels, thereby relieving hyperuricemia, and can help improve kidney function and reduce damage to the kidneys caused by excessive uric acid. Summary of the invention

[0006] The purpose of the present invention is to provide a Chinese medicine composition for treating hyperuricemia nephropathy, another purpose of the present invention is to provide a method for preparing the Chinese medicine composition, and the third purpose of the present invention is to provide the use of the Chinese medicine composition in preparing uric acid-lowering and kidney disease-improving drugs. The Chinese medicine composition of the present invention has a certain therapeutic effect on hyperuricemia and can significantly reduce uric acid levels.

[0007] The above technical purpose of the present invention is achieved through the following technical scheme: a traditional Chinese medicine composition for treating hyperuricemia nephropathy, which is made of the following raw materials in parts by weight: 15-45g of Smilax glabra, 10-20g of Poria cocos, 10-20g of Coix seed, 5-15g of Atractylodes macrocephala, and 3-9g of Licorice.

[0008] The present invention is further configured as follows: the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 30g of Rhizoma Smilacis Glabrae, 15g of Poria, 15g of Coix Seed, 10g of Atractylodes, and 6g of Licorice.

[0009] The present invention is further configured as follows: the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 15g of Smilax glabra, 10g of Poria cocos, 10g of Coix seeds, 5g of Atractylodes lancea, and 3g of Licorice.

[0010] Another object of the present invention is to provide a method for preparing a Chinese medicine composition for treating hyperuricemia nephropathy, comprising the following steps:

[0011] S1: Weigh each component and pharmaceutical excipient according to the above formula, crush the pharmaceutical excipient, and then perform sieving to obtain a uniform powder;

[0012] S2: uniformly mix all the medicinal materials and medicinal excipients processed in step S1, stir them fully during mixing, and perform decoction for multiple times;

[0013] S3: combining the decoctions obtained from each decoction in step S2, and stirring them evenly, the combined decoction is a preliminary Chinese medicine composition for treating hyperuricemia nephropathy;

[0014] S4: The combined medicinal liquid in step S3 is further concentrated in the decoction pot over a low heat. The concentrated medicinal liquid should be naturally cooled to room temperature for storage.

[0015] The present invention is further configured as follows: in step S4, the drug solution is concentrated until 2 g of crude drug is contained in every 1 ml of the drug solution, that is, the drug solution is concentrated in color and has a viscous texture, and the process is stopped.

[0016] Another object of the present invention is to provide a Chinese medicine composition for treating hyperuricemia nephropathy and its use in preparing drugs for lowering uric acid and improving kidney lesions.

[0017] The pharmacological properties of the drug of the present invention are as follows:

[0018] Smilax glabra: sweet, light, neutral, enters the liver and stomach meridians, detoxifies and removes dampness, dredges joints, removes dampness and turbidity, clears heat and reduces swelling;

[0019] Poria: sweet, light, neutral, enters the heart, lung, spleen, and kidney meridians, promotes diuresis and eliminates dampness, strengthens the spleen and calms the mind, soothes the heart and improves intelligence, resolves phlegm and relieves cough;

[0020] Coix seeds: sweet, light, slightly cold, enter the spleen, stomach, and lung meridians, promote diuresis and eliminate dampness, strengthen the spleen and stop diarrhea, clear away heat and discharge pus, and relax muscles and activate collaterals;

[0021] Atractylodes: bitter, pungent, warm, enters the spleen and stomach meridians, strengthens the spleen and dries dampness, dispels wind and cold, regulates qi and stabilizes pregnancy;

[0022] Licorice: sweet, neutral, enters the spleen, stomach, heart, and lung meridians, tonifies the spleen and replenishes Qi, moistens the lungs and relieves cough, harmonizes the stomach and relieves urgency, detoxifies and harmonizes various medicines.

[0023] The therapeutic mechanism of the present invention is: the Chinese medicine composition comprises the following five medicinal materials: Smilax glabra, Poria cocos, Coix seeds, Atractylodes macrocephala, and Licorice, each of which has its own characteristics and works together to regulate hyperuricemia nephropathy. The following is the therapeutic mechanism of each medicinal material and its synergistic effect:

[0024] With its detoxifying and dehumidifying properties, Chinese Smilax glabra can clear out damp-heat toxins in the body and reduce the accumulation of uric acid in the body. Its function of clearing joints is suitable for joint pain and swelling symptoms caused by hyperuricemia, while promoting the excretion of uric acid and protecting kidney function. In addition, Chinese Smilax glabra has certain anti-inflammatory and liver-protecting effects, which help prevent damage to the kidneys and other organs caused by high uric acid. The diuretic and dehumidifying effects of Poria cocos can effectively promote the metabolism of water in the body, help clear out excess uric acid, and relieve kidney pressure. Its spleen-strengthening effect can strengthen the spleen's transportation and transformation function, reduce the possibility of endogenous dampness and turbidity, and further prevent the deposition of uric acid. In addition, Poria cocos has the effect of calming the mind and can relieve the mental stress and anxiety caused by kidney disease.

[0025] The diuretic and dampness-infiltrating effect of coix seed can help clear dampness and turbidity in the body, promote the excretion of uric acid, and reduce the burden on the kidneys. Its spleen-strengthening effect can also enhance the spleen and stomach function, reduce the generation of internal dampness, and avoid further deposition of uric acid. Coix seed also has anti-inflammatory and immunomodulatory effects, which can reduce the inflammatory response of high uric acid to joints and kidneys; the spleen-strengthening and dampness-drying effect of Atractylodes can further strengthen the transportation and transformation function of the spleen and stomach, promote water and dampness metabolism, reduce the generation of dampness and turbidity, and facilitate the excretion of uric acid. The wind-dispelling and cold-dispersing effect of Atractylodes can improve blood circulation and prevent uric acid deposition caused by cold and dampness stagnation. In addition, it can also enhance the absorption and effect of other medicinal materials and enhance the efficacy of the prescription as a whole; the role of licorice in this prescription is mainly to coordinate the various medicines and enhance the efficacy of the overall prescription. It can also nourish the spleen and replenish qi, help the spleen and stomach restore function, and promote the metabolism of uric acid. In addition, the detoxification effect of licorice can alleviate the damage to the kidneys and other internal organs due to uric acid accumulation and further protect renal function.

[0026] The Chinese medicine composition of the present invention comprehensively regulates the spleen and stomach functions, removes dampness and turbidity in the body, and enhances the metabolism and excretion of uric acid through multiple ways such as detoxification and dehumidification, spleen invigoration and diuresis, and wind and cold dissipation. The various medicinal materials complement each other and can effectively improve the symptoms of hyperuricemia nephropathy, reduce the burden on the kidneys, protect kidney function, and prevent further deterioration of the disease.

[0027] The medicine of the present invention is mainly used for treating spleen deficiency and dampness excess; the symptoms include fatigue, loss of appetite, abdominal distension and loose stools, heaviness of limbs, dizziness, joint pain, turbid urine, pale and fat tongue, white and greasy tongue coating, and soft and slow pulse, and it has the effects of strengthening the spleen and removing dampness, promoting water and eliminating dampness.

[0028] In summary, the present invention has the following beneficial effects:

[0029] 1. The Chinese medicine composition of the present invention can effectively remove dampness and turbidity in the body, promote the excretion of uric acid, reduce the burden on the kidneys, and prevent excessive accumulation of uric acid in the body through the effects of promoting diuresis and eliminating dampness, clearing away heat and detoxifying; the medicinal materials such as Atractylodes lancea, Coix seeds, and Poria in the medicine have the effects of strengthening the spleen and drying dampness, which helps to improve the weak state of the spleen and stomach, enhance the digestion and absorption function, reduce the possibility of endogenous dampness and turbidity, and thus improve the physical condition of patients with hyperuricemia.

[0030] 2. The smilax glabra and coix seed in the medicine of the present invention have anti-inflammatory effects, can reduce the inflammatory response caused by hyperuricemia, relieve joint pain and swelling symptoms, and enhance the patient's quality of life; through the synergistic effect of multiple drugs, the prescription can effectively protect kidney function, prevent kidney damage caused by uric acid accumulation, and play a good therapeutic and preventive role. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Figure 1 Schematic diagram of HE staining results of kidney in an embodiment of the present invention;

[0032] Among them, Figure A is a schematic diagram of the HE staining results of the kidneys in the blank group; Figure B is a schematic diagram of the HE staining results of the kidneys in the model group; Figure C is a schematic diagram of the HE staining results of the kidneys in the traditional Chinese medicine group; and Figure D is a schematic diagram of the HE staining results of the kidneys in the positive drug group. DETAILED DESCRIPTION

[0033] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended only to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples without specifying specific conditions are usually performed under normal conditions or according to the conditions recommended by the manufacturer. Unless otherwise stated, all percentages, ratios, proportions, or parts are by weight.

[0034] Example 1: A Chinese medicine composition for treating hyperuricemia nephropathy, the components of the medicine include medicinal materials and pharmaceutical excipients, and are made from the following raw materials in the following weight proportions: 30g of Smilax glabra, 15g of Poria cocos, 15g of Coix seed, 10g of Atractylodes lancea, and 6g of Licorice.

[0035] The preparation method of the water decoction of the above medicine is:

[0036] S1: Preparation of medicinal materials and pharmaceutical excipients

[0037] Weigh the following medicinal materials: 30g of Smilax glabra, 15g of Poria cocos, 15g of Coix seeds, 10g of Atractylodes lancea, and 6g of Licorice root;

[0038] Medicinal material processing: Crush the medicinal excipients and then sieve them to obtain uniform powder; grind Poria cocos, licorice, coix seed and Atractylodes lancea into coarse powder respectively. The mesh size of the coarse powder is generally not less than 60 meshes to ensure that the medicinal materials can fully release their active ingredients during the decoction process.

[0039] S2: Mixing and multiple decoctions of medicinal materials

[0040] Mixing medicinal materials: uniformly mix all the medicinal materials and medicinal excipients processed in step S1; fully stir during mixing to ensure uniform distribution and effect of each medicinal material during the decoction process;

[0041] First decoction: put the mixed herbs in a decoction pot, add enough water, usually 6-8 times the total amount of herbs, soak the herbs for about 30 minutes, then start decoction, first boil over high heat, then turn to low heat to keep it at a slight boil, decoct for 30-45 minutes, after the decoction is finished, filter the liquid while it is hot, leaving the residue in the pot;

[0042] Second decoction: add an appropriate amount of water to the residue, which is also 6-8 times the total amount of the medicinal materials, repeat the above decoction process, decoct for 20-30 minutes, and filter the medicinal liquid again while it is hot;

[0043] Third decoction: According to the properties of the medicinal materials and experience, if you need to extract the medicinal effects more fully, you can perform a third decoction. The method is the same as the second time. The decoction time is 20-30 minutes. After the decoction is completed, filter the medicinal liquid again while it is hot.

[0044] S3: Decoction Filtration and Merging

[0045] Combine the medicinal liquid: combine the decoctions obtained from each decoction in step S2 and stir them evenly. The combined medicinal liquid is a preliminary Chinese medicine composition for treating hyperuricemia nephropathy.

[0046] S4: Concentration and preservation

[0047] Concentrated medicinal liquid: transfer the combined medicinal liquid to the concentration equipment, or continue to concentrate it in the decoction pot over low heat. The concentration process should be kept at a low temperature to avoid boiling the medicinal liquid or destroying the medicinal ingredients. Concentration should be stopped when 2g of crude drug is contained in 1ml of medicinal liquid. At this time, the medicinal liquid should be rich in color and viscous in texture;

[0048] Cooling and storage: The concentrated liquid medicine should be cooled naturally to room temperature to prevent the active ingredients from being destroyed by heat. The cooled liquid medicine should be divided into sterilized glass bottles or other sealed containers, sealed and stored in a cool and dry place or refrigerated.

[0049] Example 2: A Chinese medicine composition for treating hyperuricemia nephropathy, the components of the medicine include medicinal materials and pharmaceutical excipients, and are prepared from the following raw materials in proportion by weight: 15g of Smilax glabra, 10g of Poria cocos, 10g of Coix seeds, 5g of Atractylodes lancea, and 3g of Licorice. The preparation method of the water decoction of the above medicine is as shown in Example 1.

[0050] Experimental verification example:

[0051] 1. Test Materials

[0052] The present invention uses 28 SPF grade SD rats, 6-8 weeks old, male, weighing 250-280g, provided by Hunan Slake Jingda Experimental Animal Co., Ltd. The rats were raised in separate cages at the Animal Experiment Center of Hunan University of Traditional Chinese Medicine, and the raising conditions were as follows: temperature 22-26°C, daily temperature difference ≤3°C, relative humidity 40%-70%, light-dark alternation time 12 / 12h, and rats were free to eat and drink water. This experiment was reviewed and approved by the Animal Experiment Ethics Committee of Hunan University of Traditional Chinese Medicine.

[0053] 2. Main drugs and reagents

[0054] Chinese medicine formula: 30g of wild yam, 15g of poria, 15g of coix seed, 10g of atractylodes, and 6g of licorice.

[0055] Drugs and reagents: potassium oxonate (Aladdin, catalog number: P137112), hypoxanthine (Sigma, catalog number: V900452), sodium carboxymethyl cellulose (Aladdin, catalog number: C104984), allopurinol (Aladdin, catalog number: A105386); 0.9% sodium chloride injection; uric acid test kit was purchased from Nanjing Jiancheng Bioengineering Institute.

[0056] Preparation of the above solution: Preparation of sodium carboxymethylcellulose solution: Accurately weigh 5.000g of sodium carboxymethylcellulose (CMC-Na) powder, slowly add the weighed CMC-Na into a clean 1000mL beaker, then gradually add an appropriate amount of distilled water or physiological saline, and continue to stir the solution with a magnetic stirrer or a manual stirrer until the CMC-Na is completely dissolved to form a uniform colorless and transparent liquid. The concentration of the solution should be 0.5% (w / v), that is, 0.5g CMC-Na is contained in every 100mL of solution.

[0057] Preparation of potassium oxonate solution: Using the above-prepared 0.5% CMC-Na solution as a solvent, weigh 3 g of potassium oxonate crystals, gradually add the weighed potassium oxonate crystals into 97 mL of 0.5% CMC-Na solution, and slowly stir until the potassium oxonate is completely dissolved to form a uniform solution. The resulting solution is a 3% potassium oxonate solution.

[0058] Preparation of hypoxanthine suspension: Take 10 mg of hypoxanthine crystals and suspend them in 1 mL of 0.5% CMC-Na solution to form a 10 mg / mL hypoxanthine suspension. Hypoxanthine is not easy to completely dissolve, so it exists in a suspended form. Continuous stirring or ultrasonic vibration should be used to ensure uniform distribution of the suspension and prevent crystal precipitation.

[0059] All the prepared solutions mentioned above should be immediately put into clean glass bottles or plastic bottles and sealed to prevent contamination; and the prepared solutions should be refrigerated in a 4°C refrigerator. Low-temperature storage can reduce the degradation of solution components, maintain the activity and stability of the solution, and prevent changes in the viscosity and uniformity of the solution.

[0060] 3. Animal grouping, modeling and drug administration

[0061] ① Animal grouping: 28 SD rats were randomly divided into a normal group, a model group, and a Chinese medicine group, with 7 rats in each group.

[0062] ② Modeling: Except for the normal control group, rats in each group were intraperitoneally injected with 300 mg / kg of 3% potassium oxonate suspension and gavaged with 100 mg / kg hypoxanthine once a day for 7 consecutive days to establish the HUA model. The drugs were continuously administered during the modeling period.

[0063] ③Administration: Chinese medicine group: 30g of Smilax glabra, 15g of Poria cocos, 15g of Coix seeds, 10g of Atractylodes macrocephala, and 6g of Licorice.

[0064] The above Chinese medicinal materials are mixed in proportion, decocted in water, filtered, and concentrated to 2g of crude drug per ml.

[0065] The drug dosage was calculated according to the animal surface area-dose conversion method, based on the daily dose of crude drugs for a 70 kg adult. The uric acid-lowering formula was administered intragastrically at 6.84 g / (kg·d).

[0066] IV. Sampling and index testing

[0067] 1. Modeling and sampling: After the last administration of the experimental rats, wait for 1 hour to ensure that the drug can fully take effect in the body. Start modeling 1 hour after the last administration. 2 hours after modeling, the experimental animals are anesthetized to ensure that the animals do not feel pain during the sampling process. The anesthesia method can choose the conventional sodium pentobarbital small animal anesthetic; under anesthesia, use a sterile syringe to collect blood samples from the heart or tail vein of the animal. The collected blood should be immediately placed in an anticoagulant tube to avoid blood coagulation. The collected blood samples are centrifuged at 3000rpm for 10 minutes at 4°C to separate the supernatant. The separated serum should be quickly transferred to a clean EP tube and stored in a -80°C refrigerator for uric acid determination.

[0068] 2. Kidney sampling and processing: After blood collection, quickly open the abdominal cavity to expose the kidneys, carefully remove the kidneys from the abdominal cavity, weigh the left and right kidneys with a precision balance, and record their weights; immediately place the weighed left kidney in a pre-prepared 4% paraformaldehyde solution and fix it for 24 hours to prevent degradation of cell structure and components; after weighing the right kidney, use liquid nitrogen to quickly freeze the kidney tissue. The frozen right kidney should be immediately stored in an ultra-low temperature refrigerator at -80°C for subsequent molecular biology testing.

[0069] 3. Determination of uric acid, creatinine and urea nitrogen content: According to the uric acid, creatinine and urea nitrogen determination kit used in the experiment, take an appropriate amount of separated serum sample, perform sample pretreatment according to the requirements of the kit instructions, add the treated serum sample to the enzyme-linked immunosorbent plate, add various reagents according to the instructions of the kit instructions, mix well, incubate at the specified temperature of 37°C for 10 minutes, read the OD value using an enzyme reader, and measure at wavelengths of 510nm (uric acid), 546nm (creatinine), and 520nm (urea nitrogen), respectively, and calculate the specific contents of uric acid, creatinine, and urea nitrogen in serum according to the standard curve.

[0070] 4. Hematoxylin-eosin (HE) staining to observe pathological changes in renal tissue: After fixation, the renal tissue needs to be dehydrated in a gradient ethanol solution, with each level of ethanol soaking time being 1 hour. The dehydrated tissue needs to be soaked in xylene, usually in two steps, with each step soaking for 15-30 minutes, so that the renal tissue can be completely transparent. The transparent renal tissue is placed in melted paraffin, usually embedded at 60°C. After the paraffin completely embeds the tissue, it is cooled and solidified, and then cut into 4-6 micron thick slices.

[0071] After the paraffin-embedded tissue is sliced, it is placed on a slide, and then dewaxed, rehydrated, and then HE stained. Hematoxylin staining is used to stain the nucleus, and eosin staining is used to stain the cytoplasm. After staining, the slide is sealed with neutral gum to ensure that the seal is flat and free of bubbles. After sealing, an inverted microscope is used for observation, focusing on the pathological changes of kidney tissue, such as tubular damage and glomerular lesions. Finally, a microscope is used to take pictures and record the observed pathological changes.

[0072] 5. Statistical Processing

[0073] SPSS 25.0 software was used for statistical analysis. If the data were in accordance with normal distribution and the variance was homogeneous between groups, the LSD method was used. If the variance was not homogeneous, the Dunnett's T3 method was used. If the data were not in accordance with normal distribution, nonparametric tests were used. P < 0.05 was considered statistically significant.

[0074] VI. Test Results

[0075] The test results of the above uric acid, creatinine and urea nitrogen content determination are shown in Table 1 below:

[0076] Table 1 Uric acid, creatinine, urea nitrogen test results

[0077]

[0078] The above-mentioned experimental results of uric acid, creatinine and urea nitrogen content determination showed that the normal group rats did not undergo any modeling operation and drug intervention, and the serum uric acid, creatinine and urea nitrogen levels remained at the basal level without obvious fluctuations. This result shows that under normal physiological conditions, the uric acid, creatinine and urea nitrogen metabolism functions of SD rats are normal; during the modeling process, the model group rats were intraperitoneally injected with 3% potassium oxonate suspension (300 mg / kg) and gavage with hypoxanthine (100 mg / kg). After 7 consecutive days, the serum uric acid, creatinine and urea nitrogen levels increased significantly, which shows that the modeling method successfully induced a hyperuricemia (HUA) model and renal damage, verifying the effectiveness of the modeling.

[0079] The results showed that the serum uric acid, creatinine and urea nitrogen levels of rats that received the uric acid-lowering Chinese medicine prescription during modeling were significantly lower than those of the model group, indicating that the Chinese medicine prescription has a certain therapeutic effect on hyperuricemia and can effectively reduce the levels of uric acid, creatinine and urea nitrogen. Statistical analysis showed that the difference in uric acid levels between the model group and the normal group was significant (P<0.05), indicating that the modeling was successful. At the same time, the difference in uric acid levels between the Chinese medicine group and the model group was also significant (P<0.05), further proving the therapeutic effect of the Chinese medicine prescription, showing a significant uric acid-lowering effect.

[0080] The above kidney HE staining results are shown in the attached Figure 1 As shown in the figure, the results of kidney HE staining showed that the renal tissue structure of rats in the normal group was clear, the tubules and glomeruli were normal in morphology, and there were no obvious pathological changes. The epithelial cells of the renal tubules were arranged neatly, the nuclei were round and located in the center, and there was no inflammatory cell infiltration in the matrix, indicating that the renal tissue was in a healthy state. Obvious pathological changes were observed in the renal tissue of rats in the model group. The renal tubules showed varying degrees of expansion and deformation, some renal tubular epithelial cells were necrotic and detached, and the glomerular structure was blurred. Obvious inflammatory cell infiltration was seen in the renal interstitium, indicating that the renal damage was more serious. This result is consistent with the renal damage caused by hyperuricemia, indicating that the hyperuricemia model successfully induced renal lesions.

[0081] The renal tissue structure of rats in the Chinese medicine group was significantly improved compared with that in the model group. The renal tubular epithelial cells were arranged more neatly, the number of necrotic and detached cells was significantly reduced, and the glomerular structure was clearer. Although slight inflammatory cell infiltration was still visible, the overall degree of lesions was significantly reduced. This shows that the Chinese medicine prescription has a certain protective effect on renal damage caused by hyperuricemia and can reduce the degree of lesions.

[0082] This specific embodiment is merely an explanation of the present invention and is not a limitation of the present invention. After reading this specification, those skilled in the art may make non-creative modifications to the present embodiment as needed. However, as long as they are within the scope of the claims of the present invention, they are protected by the patent law.

Claims

1. A Chinese medicine composition for treating hyperuricemia nephropathy, characterized in that: The invention is prepared from the following raw materials in parts by weight: 15-45g of Smilax glabra, 10-20g of Poria cocos, 10-20g of Coix seeds, 5-15g of Atractylodes lancea and 3-9g of Licorice root.

2. A Chinese medicine composition for treating hyperuricemia nephropathy according to claim 1, characterized in that: The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 30g of smilax glabra, 15g of tuckahoe, 15g of coix seed, 10g of atractylodes, and 6g of liquorice.

3. A Chinese medicine composition for treating hyperuricemia nephropathy according to claim 1, characterized in that: The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 15g of smilax glabra, 10g of tuckahoe, 10g of coix seed, 5g of atractylodes, and 3g of liquorice.

4. A method for preparing a Chinese medicine composition for treating hyperuricemia nephropathy, characterized in that: The following steps are involved: S1: weighing each component and pharmaceutical excipient according to the formula of claim 3, crushing the pharmaceutical excipient, and then sieving to obtain a uniform powder; S2: uniformly mix all the medicinal materials and medicinal excipients processed in step S1, stir them fully during mixing, and perform decoction for multiple times; S3: combining the decoctions obtained from each decoction in step S2, and stirring them evenly, the combined decoction is a preliminary Chinese medicine composition for treating hyperuricemia nephropathy; S4: The combined medicinal liquid in step S3 is further concentrated in the decoction pot over a low heat. The concentrated medicinal liquid should be naturally cooled to room temperature for storage.

5. A Chinese medicine composition for treating hyperuricemia nephropathy according to claim 1, characterized in that: In step S4, the medicinal liquid is concentrated until 2 g of crude drug is contained in 1 ml of the medicinal liquid, that is, the color of the medicinal liquid is rich and the texture is viscous, so the process is stopped.

6. Use of the Chinese medicine composition for treating hyperuricemia nephropathy as described in claims 1-3 in the preparation of drugs for lowering uric acid and improving kidney lesions.

Images